Telomir Pharmaceuticals, Inc.
Business
Telomir Pharmaceuticals, Inc. develops Telomir-1, an oral small-molecule metal ion regulator intended to extend telomere caps, restore cellular homeostasis, and counter oxidative stress. Its principal product candidate, Telomir-1, is investigated as a therapeutic for metal-overload and age-related conditions including Wilson’s disease, Progeria, age-related macular degeneration, Type 2 diabetes, Alzheimer’s disease, cancer, and severe viral infections by modulating iron, copper, and zinc dynamics. The company operates preclinical research and development, IND/INAD-enabling studies, and manufacturing partnerships, and holds U.S. license rights from MIRALOGX. Its development and potential commercialization activities are focused on the United States with collaborative research and manufacturing relationships internationally.
Summary from filing dated 2025-02-04
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Revenues | — | — | — | — | |
| General and administrative expenses | 8 | 10 | 600,192 | 20,941 | |
| Related party travel costs | — | 370,500 | 2 | — | |
| Research and development expenses | 2 | 2 | 2 | 833,206 | |
| Total operating costs | 11 | 12 | 4 | 854,147 | |
| Interest income | 125,644 | 48,000 | — | — | |
| Interest expense | — | −4 | −2 | — | |
| Net loss | −10 | −17 | −13 | −854,147 | |
| Basic loss per share | −0.33 | −0.56 | 0.48 | −0.03 | |
| Diluted loss per share | −0.33 | −0.56 | 0.48 | −0.03 | |
| Basic weighted average common stock shares outstanding | 32 | 30 | 27 | 27 | |
| Diluted weighted average common stock shares outstanding | 32 | 30 | 27 | 27 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 7 | 1 | 1,231 | 1,419 | — | |
| Prepaid expenses | 54,691 | 57,874 | 713 | — | — | |
| Total current assets | 7 | 1 | 435,225 | 48,730 | — | |
| Total assets | 7 | 1 | 5 | 48,730 | — | |
| Trade accounts payable and accrued liabilities | 536,769 | 587,536 | 707,187 | 404,221 | — | |
| Due to officer | 155,518 | — | — | — | — | |
| Accrued compensation - officer | 417,470 | — | — | — | — | |
| Due to related parties | 318,234 | 93,432 | 527,377 | — | — | |
| Total current liabilities | 1 | 680,968 | 1 | 986,008 | — | |
| Total liabilities | 1 | 680,968 | 1 | 986,008 | — | |
| Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding. | — | — | — | — | — | |
| Common Stock, no par value; 300,000,000 shares authorized, 34,380,971 and 29,762,671 shares issued and outstanding at December 31, 2025 and 2024, respectively. | — | — | — | — | — | |
| Additional paid-in capital | 47 | 31 | 18 | 55,000 | — | |
| Accumulated deficit | −41 | −31 | −14 | −992,278 | — | |
| Total stockholders equity | 6 | 600,000 | 3 | −937,278 | −138,131 | |
| Total liabilities and stockholders equity | 7 | 1 | 5 | 48,730 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Stock-based compensation expense | 5 | 7 | — | — | |
| Issuance of common stock for services | 840,000 | — | — | — | |
| Credit loss expenses - loan due from related party | — | 130,000 | — | — | |
| Amortization of debt issuance costs | — | 4 | 2 | — | |
| Prepaid expenses | 3,183 | −57,160 | −713 | — | |
| Trade accounts payable and accrued liabilities | −50,767 | 183,629 | 114,556 | 385,486 | |
| Due to related parties | 224,802 | — | — | — | |
| Accrued compensation - officer | 417,470 | — | — | — | |
| Net cash used in operating activities | −4 | −5 | −4 | −468,661 | |
| Payments under related party line of credit | — | −101,000 | — | — | |
| Repayments to related party | — | −433,945 | 2 | 462,391 | |
| Repayment from officer | 155,518 | — | — | — | |
| Proceeds from warrant exercise | — | 37,300 | — | — | |
| Proceeds from sale of common stock, related party | 3 | — | — | — | |
| Net proceeds from sale of common stock | 7 | 7 | — | — | |
| Net cash provided by financing activities | 10 | 6 | 4 | 470,080 | |
| Net change in cash | 6 | 1 | −188 | 1,419 | |
| Cash paid for interest | — | — | — | — | |
| Cash paid for income tax | — | — | — | — | |
| Deferred offering costs charged to additional paid-in capital | — | 303,281 | — | — |